Healthcare Industry News: cancer stem cell
News Release - February 13, 2013
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development
SAN CARLOS, Calif.--(Healthcare Sales & Marketing Network)--Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today the appointment of William Reed, M.D. as Vice President, Clinical Development.Dr. Reed joins Cellerant from Cerus Corporation, where he served as Director, Clinical Research and Medical Affairs and worked on the Phase 3 clinical development of a red blood cell system in sickle cell disease or thalassemia. Prior to Cerus, Dr. Reed had been an investigator at Blood Systems Research Institute in San Francisco and a member of the clinical faculty at UCSF where he was the first Medical Director of the Human Islet and Cellular Transplantation Facility.
"Dr. Reed is an accomplished leader in the development of products in hematology and blood transfusions. I am pleased to welcome him to the Cellerant team," said Ram Mandalam, President and CEO of Cellerant. "His extensive experience in pediatric hematology/oncology and transfusion medicine will significantly benefit Cellerant in the development of CLT-008 for cord blood transplantation, leukemia and acute radiation syndrome applications and the future clinical development of our cancer stem cell program.”
“I am very excited to join Cellerant and the opportunity to work on the development of novel, cellular and antibody approaches to treat blood disorders and hematological malignancies,” said Dr. Reed. “Cancer research is a challenging and evolving field and I look forward to working closely with the Cellerant team as we seek to develop novel therapies to address significant unmet medical needs.”
Dr. Reed received his Doctor of Medicine degree from Brown University, and completed his medical training in pediatrics at Oregon Health Sciences University and in hematology/oncology at Children’s Hospital Oakland. He also received his Masters of Health Sciences in Radiation Health Science at Johns Hopkins University Bloomberg School of Public Health. He is a member or fellow of several medical societies and has published several peer-reviewed articles and abstracts.
About Cellerant Therapeutics
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008, is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome.
For more information, visit: http://www.cellerant.com.
Source: Cellerant Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
